<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Six patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and two patients with <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo>, <z:hpo ids='HP_0000001'>all</z:hpo> with severe <z:hpo ids='HP_0001903'>anemia</z:hpo> entered the study </plain></SENT>
<SENT sid="1" pm="."><plain>Before treatment reasons of secondary <z:hpo ids='HP_0001903'>anemia</z:hpo> were excluded </plain></SENT>
<SENT sid="2" pm="."><plain>Concentration of erythropoietin, iron, transferrin, ferritin were measured before, and in the second and the third month of the trial </plain></SENT>
<SENT sid="3" pm="."><plain>A r-HuEpo dosage of 80 U/kg was administered intravenously three times weekly for a minimum of three months </plain></SENT>
<SENT sid="4" pm="."><plain>Four patients finished the study </plain></SENT>
<SENT sid="5" pm="."><plain>The increase in <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> concentration by 6 g% was observed in one patient with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> subtype RA </plain></SENT>
<SENT sid="6" pm="."><plain>In three other patients who apart from r-HuEpo received chemotherapy transfusion requirements decreased by 90% </plain></SENT>
<SENT sid="7" pm="."><plain>Together with increase in <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> decrease in ferritin was observed </plain></SENT>
<SENT sid="8" pm="."><plain>The correlation between r-HuEpo and endogenous erythropoietin and ferritin was defined </plain></SENT>
</text></document>